Not Yet Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05739734

Safety of CRIS100 on Treatment Spinal Cord Injury

Clinical Safety Study of the Application of CRIS100 in Participants With Acute Spinal Cord Injury

Sponsor: Cristália Produtos Químicos Farmacêuticos Ltda.

Interventions CRIS100

Updated 5 times since 2023 Last updated: Jan 30, 2026 Started: Apr 30, 2026 Primary completion: May 31, 2027 Completion: May 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05739734, this EARLY_PHASE1 trial focuses on Thoracic Spinal Cord Injury and remains actively recruiting participants. Sponsored by Cristália Produtos Químicos Farmacêuticos Ltda., it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting EARLY_PHASE1

Status: Unknown → Not Yet Recruiting
Mar 2025 — Feb 2026 [monthly]

Unknown EARLY_PHASE1

Status: Not Yet Recruiting → Unknown
Sep 2024 — Mar 2025 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Mar 2023 — Jul 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cristália Produtos Químicos Farmacêuticos Ltda.

Data source: Cristália Produtos Químicos Farmacêuticos Ltda.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.